天然阿普托丁在阿尔茨海默病中的多功能作用:来自DFT和MD研究的见解
Thi Chinh Ngo1,2, Hoang Linh Nguyen2,3, Dinh Hieu Truong1,2
1Institute of Research and Development, Duy Tan University, Da Nang 550000, Viet Nam.
The journal of physical chemistry. B
|December 9, 2025
概括
阿普托丁A通过清除有害基质和抑制粉样β (Aβ) 聚合,对阿尔茨海默病 (AD) 显示出前景. 这种化合物有效地减少了氧化应激和金属诱导的神经毒性,提供了潜在的治疗益处.
科学领域:
- 计算化学计算化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是氧化应激和粉样β (Aβ) 聚合.
- 阿普托丁A正在研究其对抗这些病理特征的潜力.
- 了解阿普托丁A的分子机制对于开发新的AD疗法至关重要.
研究的目的:
- 评估aaptodine A的抗氧化特性,特别是其激素清除和金属化能力.
- 用计算方法评估aaptodine A对粉样β (Aβ) 聚合的抑制作用.
- 探索aaptodine A作为阿尔茨海默病的潜在治疗剂.
主要方法:
- 密度函数理论 (DFT) 计算 (M06-2X,M06) 用于研究激素清除和金属离子化.
- 用分子对接和分子动力学 (MD) 模拟来研究aaptodine A与Aβ42.2的相互作用.
- 使用MM/PBSA和加速体重组图 (AWH) 方法来确定与Aβ42纤维结构的结合亲和力.
主要成果:
- 阿普托丁A有效地清除基激素 (HO·),但不能清除基激素 (HOO·).
- 它与Cu2+和Fe3+离子表现出显著的化活性,特别是在双酸盐复合体中.
- 阿普托丁A对Aβ42纤维和有毒的寡合物种表现出强烈的结合亲和力,与黄素相似.
结论:
- 阿普托丁A具有强大的抗氧化和金属化性质,对缓解AD病变产生具有重要意义.
- 它抑制Aβ聚合的能力表明它在对抗阿尔茨海默病时具有双重的作用机制.
- 阿普托丁A是一种有前途的候选人,可以作为AD的治疗策略进行进一步的研究.
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
517
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
517
01:30Dementia
487
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
487
01:23Role of Neurotransmitters in Memory
2.4K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.4K